OrganaBio

Executive Summary

OrganaBio is a Miami-based Contract Technology Development and Manufacturing Organization (CTDMO) specializing in cell and gene therapy. Founded in 2018, the company provides ethically sourced, donor-derived starting materials such as leukopaks and PBMCs, along with clinical cell processing and cGMP manufacturing services. OrganaBio's unique value proposition lies in its rapid, localized processing and recallable donor materials, which accelerate therapy development for its customers. As the cell and gene therapy market continues to grow, demand for high-quality, reliable starting materials and manufacturing services is increasing. OrganaBio is well-positioned to capitalize on this trend by offering a comprehensive suite of services that reduce supply chain complexity and time-to-clinic for developers. With a focus on quality and ethical sourcing, the company aims to become a trusted partner in the regenerative medicine ecosystem. Its pre-clinical stage and private status suggest a growth trajectory focused on building operational excellence and customer relationships.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a leading cell therapy developer55% success
• Q4 2026Expansion of cGMP manufacturing capacity70% success
• Q1 2027Launch of new donor-derived product line (e.g., NK cells or mesenchymal stem cells)60% success